+

WO1999032634A3 - Compositions derived from mycobacterium vaccae and methods for their use - Google Patents

Compositions derived from mycobacterium vaccae and methods for their use Download PDF

Info

Publication number
WO1999032634A3
WO1999032634A3 PCT/NZ1998/000189 NZ9800189W WO9932634A3 WO 1999032634 A3 WO1999032634 A3 WO 1999032634A3 NZ 9800189 W NZ9800189 W NZ 9800189W WO 9932634 A3 WO9932634 A3 WO 9932634A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
vaccae
delipidated
mycobacterium vaccae
compositions derived
Prior art date
Application number
PCT/NZ1998/000189
Other languages
French (fr)
Other versions
WO1999032634A2 (en
Inventor
Paul Tan
James Watson
Elizabeth S Visser
Margot A Skinner
Ross L Prestidge
Original Assignee
Genesis Res & Dev Corp Ltd
Paul Tan
James Watson
Elizabeth S Visser
Margot A Skinner
Ross L Prestidge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/997,362 external-priority patent/US5985287A/en
Priority claimed from US08/997,080 external-priority patent/US5968524A/en
Priority claimed from US09/095,855 external-priority patent/US6160093A/en
Priority claimed from US09/205,426 external-priority patent/US6406704B1/en
Priority to MXPA00006168A priority Critical patent/MXPA00006168A/en
Priority to HU0100352A priority patent/HUP0100352A2/en
Priority to JP2000525553A priority patent/JP2002514385A/en
Priority to AU18936/99A priority patent/AU746311B2/en
Application filed by Genesis Res & Dev Corp Ltd, Paul Tan, James Watson, Elizabeth S Visser, Margot A Skinner, Ross L Prestidge filed Critical Genesis Res & Dev Corp Ltd
Priority to BR9814432-4A priority patent/BR9814432A/en
Priority to CA002315539A priority patent/CA2315539A1/en
Priority to KR1020007006505A priority patent/KR20010033132A/en
Priority to EP98963665A priority patent/EP1044273A2/en
Priority to NZ505834A priority patent/NZ505834A/en
Priority to IL13682198A priority patent/IL136821A0/en
Publication of WO1999032634A2 publication Critical patent/WO1999032634A2/en
Publication of WO1999032634A3 publication Critical patent/WO1999032634A3/en
Priority to NO20003261A priority patent/NO20003261L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides compositions which are present in or may be derived from Mycobacterium vaccae, together with methods for their use in the treatment, prevention and detection of disorders including infectious diseases, immune disorders and cancer. Methods for enhancing the immune response to an antigen including administration of M. vaccae culture filtrate, delipidated M. vaccae cells, delipidated and deglycolipidated M. vaccae cells depleted of mycolic acids, and delipidated and deglycolipidated M.vaccae cells depleted of mycolic acids and arabinogalactan are also provided.
PCT/NZ1998/000189 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use WO1999032634A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020007006505A KR20010033132A (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use
EP98963665A EP1044273A2 (en) 1997-12-23 1998-12-23 COMPOSITIONS DERIVED FROM $i(MYCOBACTERIUM VACCAE) AND METHODS FOR THEIR USE
NZ505834A NZ505834A (en) 1997-12-23 1998-12-23 Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
HU0100352A HUP0100352A2 (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use
IL13682198A IL136821A0 (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use
JP2000525553A JP2002514385A (en) 1997-12-23 1998-12-23 COMPOSITIONS DERIVED FROM MYCOBACTERIUM BACKEY AND USE THEREOF
AU18936/99A AU746311B2 (en) 1997-12-23 1998-12-23 Compositions derived from (mycobacterium vaccae) and methods for their use
MXPA00006168A MXPA00006168A (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae.
BR9814432-4A BR9814432A (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and process for their use
CA002315539A CA2315539A1 (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use
NO20003261A NO20003261L (en) 1997-12-23 2000-06-22 Mixtures derived from Mycobacterium vaccae and methods for their use

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US99662497A 1997-12-23 1997-12-23
US08/997,080 1997-12-23
US08/997,362 1997-12-23
US08/996,624 1997-12-23
US08/997,362 US5985287A (en) 1996-08-29 1997-12-23 Compounds and methods for treatment and diagnosis of mycobacterial infections
US08/997,080 US5968524A (en) 1997-12-23 1997-12-23 Methods and compounds for the treatment of immunologically-mediated psoriasis
US09/095,855 1998-06-11
US09/095,855 US6160093A (en) 1996-08-29 1998-06-11 Compounds and methods for treatment and diagnosis of mycobacterial infections
US15618198A 1998-09-17 1998-09-17
US09/156,181 1998-09-17
US09/205,426 US6406704B1 (en) 1996-08-29 1998-12-04 Compounds and methods for treatment and diagnosis of mycobacterial infections
US09/205,426 1998-12-04

Publications (2)

Publication Number Publication Date
WO1999032634A2 WO1999032634A2 (en) 1999-07-01
WO1999032634A3 true WO1999032634A3 (en) 1999-12-02

Family

ID=27557521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ1998/000189 WO1999032634A2 (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use

Country Status (15)

Country Link
EP (1) EP1044273A2 (en)
JP (1) JP2002514385A (en)
CN (1) CN1294632A (en)
AU (1) AU746311B2 (en)
BR (1) BR9814432A (en)
CA (1) CA2315539A1 (en)
HU (1) HUP0100352A2 (en)
ID (1) ID26327A (en)
IL (1) IL136821A0 (en)
MX (1) MXPA00006168A (en)
NO (1) NO20003261L (en)
NZ (1) NZ505834A (en)
PL (1) PL341697A1 (en)
TR (1) TR200001948T2 (en)
WO (1) WO1999032634A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498933B2 (en) 1999-04-06 2009-03-03 911Ep, Inc. Replaceable LED modules

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
JP4415200B2 (en) * 1999-01-29 2010-02-17 大塚製薬株式会社 Late-growing mycobacterial polypeptide
GB9903539D0 (en) 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US6350457B1 (en) * 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
AU784847B2 (en) * 1999-07-12 2006-07-06 Genesis Research And Development Corporation Limited Compounds for treatment of infectious and immune system disorders and methods for their use
US7217554B2 (en) 1999-08-31 2007-05-15 Novozymes A/S Proteases and variants thereof
AU7901300A (en) * 1999-08-31 2001-03-26 Stefan Bossmann Method for producing a channel-forming protein
AU6820000A (en) 1999-08-31 2001-03-26 Novozymes A/S Novel proteases and variants thereof
US6361776B1 (en) * 1999-12-06 2002-03-26 Genesis Research & Development Corp. Ltd. Compounds isolated from M. vaccae and their use in modulation of immune responses
AU2403901A (en) * 1999-12-28 2001-07-09 Ichiro Azuma Maturation-promoting agent for immature dendritic cells
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
AU2002309857A1 (en) * 2001-05-11 2002-12-03 Corixa Corporation Vaccines for the treatment of autoimmune disease
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
GB0303507D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
SG11201605595YA (en) * 2014-01-09 2016-08-30 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
CN115804834A (en) * 2021-08-10 2023-03-17 昆明医科大学 Polypeptide with functions of improving immunity, resisting tumors and prolonging life and application thereof
CN119162167B (en) * 2024-11-21 2025-03-11 四川大学华西医院 Extraction method of mycobacteria genome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002542A1 (en) * 1989-08-25 1991-03-07 University College London Treatment of chronic inflammatory conditions
EP0763361A2 (en) * 1992-02-21 1997-03-19 University College London Mycobacterium vaccae for treatment of long term autoimmune conditions
WO1998008542A2 (en) * 1996-08-29 1998-03-05 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002542A1 (en) * 1989-08-25 1991-03-07 University College London Treatment of chronic inflammatory conditions
EP0763361A2 (en) * 1992-02-21 1997-03-19 University College London Mycobacterium vaccae for treatment of long term autoimmune conditions
WO1998008542A2 (en) * 1996-08-29 1998-03-05 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EMBL database entry MV17958; accession number U17958; 22-Dec-1994; Kapur V. et al.: 'Mycobacterium vaccae 65 kDa heat shock protein gene, partial cds.' *
KAPUR V. ET AL.: "RAPID MYCOBACTERIUM SPECIES ASSIGNMENT AND UNAMBIGUOUS IDENTIFICATION OF MUTATIONS ASSOCIATED WITH ANTIMICROBIALS RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS BY AUTOMATED DNA SEQUENCING", ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, vol. 119, no. 2, 1 February 1995 (1995-02-01), pages 131 - 138, XP000572767 *
SKINNER M. A. ET AL.: "IMMUNIZATION WITH HEAT-KILLED MYCOBACTERIUM VACCAE STIMULATES CD8+CYTOTOXIC T CELLS SPECIFIC FOR MACROPHAGES INFECTED WITH MYCOBACTERIUM TUBERCULOSIS", INFECTION AND IMMUNITY, vol. 65, no. 11, 1 November 1997 (1997-11-01), pages 4525 - 4530, XP002060474 *
SOINI H. AND VILJANEN M. K.: "Diversity of the 32-kilodalton protein gene may form a basis for species determination of potentially pathogenic mycobacterial species.", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 35, no. 3, March 1997 (1997-03-01), pages 769 - 773, XP002094599 *
STANFORD J L: "IMPROVING ON BCG", APMIS, vol. 99, no. 2, 1 January 1991 (1991-01-01), pages 103 - 113, XP000616012 *
STANFORD J. L. ET AL.: "Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis.", VACCINE, vol. 8, December 1990 (1990-12-01), pages 525 - 530, XP002106918 *
YOUNG R. A. ET AL.: "DISSECTION OF MYCOBACTERIUM TUBERCULOSIS ANTIGENS USING RECOMBINANT DNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 82, 1 May 1985 (1985-05-01), pages 2583 - 2587, XP002034045 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498933B2 (en) 1999-04-06 2009-03-03 911Ep, Inc. Replaceable LED modules

Also Published As

Publication number Publication date
WO1999032634A2 (en) 1999-07-01
CN1294632A (en) 2001-05-09
HUP0100352A2 (en) 2001-06-28
BR9814432A (en) 2000-10-10
AU746311B2 (en) 2002-04-18
TR200001948T2 (en) 2001-02-21
IL136821A0 (en) 2001-06-14
ID26327A (en) 2000-12-14
PL341697A1 (en) 2001-04-23
JP2002514385A (en) 2002-05-21
NZ505834A (en) 2002-12-20
NO20003261D0 (en) 2000-06-22
AU1893699A (en) 1999-07-12
EP1044273A2 (en) 2000-10-18
NO20003261L (en) 2000-08-22
MXPA00006168A (en) 2005-02-24
CA2315539A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
WO1999032634A3 (en) Compositions derived from mycobacterium vaccae and methods for their use
WO2000023955A8 (en) Virus-like particles for the induction of autoantibodies
WO1998055495A3 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
IL192679A0 (en) Aglyco products and uses thereof
CA2259140A1 (en) Method of activating dendritic cells
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
CA2250078A1 (en) Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
WO1998016184A3 (en) Purine l-nucleosides, analogs and uses thereof
ZA987540B (en) Process for the preparation of stanol esters, and use thereof.
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
WO2001036487A3 (en) Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO1999003976A3 (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
WO1999064464A3 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
WO2001051008A3 (en) Selective activation of a th1 or th2 lymphocyte regulated immune response
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
WO1999049876A3 (en) Bacterial or yeast extracts which stimulate the production of defensins and methods of use thereof
DE69839943D1 (en) PREVENT IMMUNOACTIVITY THROUGH INHIBITION OR INHIBITION OF ANTIGEN-PRESENTING CELLS
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
WO2000027429A3 (en) Vaccine against papillomatous digital dermatitis (pdd)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 136821

Country of ref document: IL

Ref document number: 98813781.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1020007006505

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 18936/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2315539

Country of ref document: CA

Ref document number: 2315539

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2000-2321

Country of ref document: CZ

Ref document number: PA/a/2000/006168

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000/01948

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1998963665

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 505834

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1998963665

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-2321

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007006505

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 18936/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998963665

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020007006505

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载